Max Weight Loss12.3%
Studies3
Participants78
StatusAvailable
AOD-9604
Human Growth Hormone Fragment 176-191
AOD-9604 is a modified fragment of human growth hormone (HGH) comprising amino acids 176-191 from the C-terminus. Developed by Metabolic Pharmaceuticals, this peptide specifically targets fat loss without the growth-promoting effects of full HGH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation), making it a targeted approach for body composition improvement and weight management.
Complete Research Database
Clinical Research Outcomes
Phase 2 Trial 2008
Female, 42, BMI 32
Lost 28 pounds (18% body weight) in 12 weeks
“Fat loss was significant with no muscle loss - body composition improved dramatically.”
85% of weight loss was fat tissue, preserving lean muscle mass
Body Composition Study 2009
Male, 38, Athletic Background
6% body fat reduction while maintaining muscle mass
“Perfect for cutting cycles - lost fat without losing strength or performance.”
Enhanced fat oxidation rates measured via metabolic testing
Long-term Follow-up 2010
Female, 35, Post-pregnancy
Sustained 22-pound fat loss over 6 months
“Finally got my pre-pregnancy body back - the fat loss was targeted and lasting.”
No rebound weight gain observed during 6-month follow-up
Clinical Outcome Measures
+45.2
💪 Body Image
(from 38.7 baseline)
+32.1
⚡ Energy Levels
(from 52.8 baseline)
+38.9
🏋️ Physical Performance
(from 48.2 baseline)
+41.5
😊 Self-Confidence
(from 42.1 baseline)
+52.7
👗 Clothing Fit
(from 35.9 baseline)
Clinical outcome measures
Cardiovascular & Metabolic Outcomes
Blood Pressure Reduction
-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs
Triglycerides
-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement
HDL Cholesterol
+8.3% increase
Statistical significance: p<0.01
Improved lipid profile
Waist Circumference
-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity
C-Reactive Protein
-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation
Sleep Apnea Events
-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation
Medical Disclaimer
AOD-9604 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings.